Assessment of controlled release buccal inserts containing pilocarpine hydrochloride: a multicentre, double-blind, placebo-controlled, randomised, cross-over study in patients diagnosed with Sjögren's Syndrome

Submission date	Recruitment status	Prospectively registered
23/09/2002	No longer recruiting	☐ Protocol
Registration date	Overall study status	Statistical analysis plan
23/09/2002	Completed	☐ Results
Last Edited	Condition category	Individual participant data
24/05/2016	Musculoskeletal Diseases	Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Mr John Hamburger

Contact details

The University of Birmingham School of Dentistry St Chad's Queensway Birmingham United Kingdom B4 6NN +44 (0)121 237 2888 j.hamburger@bham.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

PILO-BUC-002

Study information

Scientific Title

Assessment of controlled release buccal inserts containing pilocarpine hydrochloride: a multicentre, double-blind, placebo-controlled, randomised, cross-over study in patients diagnosed with Sjögren's Syndrome

Study objectives

Not provided at time of registration

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Multi-centre double-blind placebo-controlled randomised cross-over study

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Sjögren's Syndrome

Interventions

This trial is a 'cross-over' study with four treatment cycles. For each treatment cycle, patients will be provided with 12 buccal inserts, containing one of the following: 2.5, 5 or 10 mg pilocarpine or placebo. A treatment cycle is four days long, however, there will be a three day washout period between each new dose. The buccal insert is a hydrogel polymer with pilocarpine dispersed throughout the matrix. Each buccal insert should be inserted high in the upper buccal sulcus between the buccal mucosa and gingivae towards the back of the mouth and remain in situ for at least three hours. One buccal insert should be inserted three times daily in the period between meals.

Intervention Type

Other

Phase

Not Specified

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/01/2002

Completion date

31/12/2002

Eligibility

Key inclusion criteria

Approximately 30 patients with primary or secondary Sjögren's Syndrome, as diagnosed by the modified European Diagnostic Classification, will be enrolled into the study, to accrue 25 evaluable patients

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

30

Key exclusion criteria

Not provided at time of registration

Date of first enrolment

01/01/2002

Date of final enrolment

31/12/2002

Locations

Countries of recruitment

England

United Kingdom

Study participating centre
The University of Birmingham
Birmingham
United Kingdom
B4 6NN

Sponsor information

Organisation

Controlled Therapeutics (Scotland) Ltd

Sponsor details

1 Redwood Place Peel Park Campus East Kilbride United Kingdom G74 5PB

Sponsor type

Industry

ROR

https://ror.org/03e9kb581

Funder(s)

Funder type

Industry

Funder Name

Controlled Therapeutics (Scotland) Ltd (UK)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date
Individual participant data (IPD) sharing plan

IPD sharing plan summaryNot provided at time of registration